Anti-CD20 treatment for B-cell malignancies: current status and future directions

References

• Vital EM, Dass S, Emery P, et al. B-cell depletion. In: Hochberg MC, Silman AJ, Smolen JSeditors. Rheumatology. 6th ed. Philadelphia: ScienceDirect; 2015. p. 472–478.
   Google Scholar
• Middleton O, Wheadon H, Michie AM. Classical complement pathway. In: Ratcliffe MJH, editor. Encyclopedia of immunobiology. Oxford: Academic Press; 2016. p. 318–324.
   Google Scholar
• Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999 Mar;5(3):611–615.
   PubMed Web of Science ®Google Scholar
• Horna P, Nowakowski G, Endell J, et al. Comparative assessment of surface CD19 and CD20 expression on B-cell lymphomas from clinical biopsies: implications for targeted therapies. Blood. 2019;134(Supplement_1):5345.
   Web of Science ®Google Scholar
• Polyak MJ, Li H, Shariat N, et al. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem. 2008 July 4;283(27):18545–18552.
   PubMed Web of Science ®Google Scholar
• Rougé L, Chiang N, Steffek M, et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020 Mar 13;367(6483):1224–1230.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997 Sep 15;90(6):2188–2195.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825–2833.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Klein C, Oya N, et al. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017 Feb;34(2):324–356.
   PubMed Web of Science ®Google Scholar
• Boross P, Leusen JHW. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012 Nov 20;2(6):676–690.
   PubMed Web of Science ®Google Scholar
• Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002 Jan;87(1):33–43.
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol. 2001 Sep;114(4):800–809.
   PubMed Web of Science ®Google Scholar
• Lim SH, Levy R. Translational medicine in action: anti-CD20 therapy in lymphoma. J Immunol. 2014 Aug 15;193(4):1519–1524.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010 Sep 23;116(12):2040–2045.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) group. Lancet Oncol. 2006 May;7(5):379–391.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164–1174.
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007 May 2;99(9):706–714.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v78–84.
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Linden E, Termuhlen AM, et al. Lymphoma in adolescents and young adults. Semin Oncol. 2009 Oct;36(5):381–418.
   PubMed Web of Science ®Google Scholar
• Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v116–25.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Vitolo U, Kimby E, et al. ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2012 Mar;24(3):561–576.
   PubMed Web of Science ®Google Scholar
• Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma - novel and emerging therapies. Cancer Manag Res. 2013 Aug;5:251–269.
   PubMedGoogle Scholar
• Rivas-Delgado A, Magnano L, Moreno-Velázquez M, et al. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol. 2019 Mar;184(5):753–759.
   PubMed Web of Science ®Google Scholar
• Fishelson Z, Donin N, Zell S, et al. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol. 2003 Sep;40(2–4):109–123.
   PubMed Web of Science ®Google Scholar
• Takei K, ki T, Sawada U, et al. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res. 2006 May;30(5):625–631.
   PubMed Web of Science ®Google Scholar
• Klepfish A, Gilles L, Ioannis K, et al. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann N Y Acad Sci. 2009 Sep;1173:865–873.
   PubMed Web of Science ®Google Scholar
• Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med. 2008 Mar 25;5(3):e64.
   PubMed Web of Science ®Google Scholar
• Wang SY, Veeramani S, Racila E, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood. 2009 Dec 17;114(26):5322–5330.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002 Feb 1;99(3):754–758.
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003 Nov 1;21(21):3940–3947.
   PubMed Web of Science ®Google Scholar
• Strefford JC, Nowicka M, Hargreaves C, et al. Prognostic impact of germ-line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) single nucleotide polymorphisms in lymphoma patients treated with obinutuzumab or rituximab in combination with chemotherapy: results from the phase III GALLIUM and GOYA clinical trials. Blood. 2018;132:4109.
   Web of Science ®Google Scholar
• Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res. 2007 Feb 1;67(3):1270–1281.
   PubMed Web of Science ®Google Scholar
• Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, et al. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res. 2008 Mar 1;14(5):1550–1560.
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010 Jun 24;115(25):5191–5201.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008 Mar 1;14(5):1561–1570.
   PubMed Web of Science ®Google Scholar
• Terui Y, Mishima Y, Sugimura N, et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin’s lymphoma. Clin Cancer Res. 2009 Apr 1;15(7):2523–2530.
   PubMed Web of Science ®Google Scholar
• Pedersen AE, Jungersen MB, Pedersen CD. Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies. Immunology. 2011;133(2):239–245.
   PubMed Web of Science ®Google Scholar
• Beum PV, Kennedy AD, Williams ME, et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol. 2006 Feb 15;176(4):2600–2609.
   PubMed Web of Science ®Google Scholar
• Li Y, Williams ME, Cousar JB, et al. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol. 2007 Sep 15;179(6):4263–4271.
   PubMed Web of Science ®Google Scholar
• Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol. 2008 Aug 15;181(4):2916–2924.
   PubMed Web of Science ®Google Scholar
• Vaughan AT, Chan CH, Klein C, et al. Activatory and inhibitory Fcgamma receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain. J Biol Chem. 2015 Feb 27;290(9):5424–5437.
   PubMed Web of Science ®Google Scholar
• Vaughan AT, Iriyama C, Beers SA, et al. Inhibitory FcgammaRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood. 2014 Jan 30;123(5):669–677.
   PubMed Web of Science ®Google Scholar
• Lim SH, Vaughan AT, Ashton-Key M, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011 Sep 1;118(9):2530–2540.
   PubMed Web of Science ®Google Scholar
• Roghanian A, Teige I, Martensson L, et al. Antagonistic human FcgammaRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer Cell. 2015 Apr 13;27(4):473–488.
   PubMed Web of Science ®Google Scholar
• Davies A, Berge C, Boehnke A, et al. Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017 Oct;34(10):2210–2231.
   PubMed Web of Science ®Google Scholar
• Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs. 2011 Feb 1;25(1):13–25.
   PubMed Web of Science ®Google Scholar
• Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013 Jan–Feb;5(1):22–33.
   PubMed Web of Science ®Google Scholar
• Genentech, Inc. Highlights of prescribing information. GAZYVA® (obinutuzumab) injection, for intravenous use. Initial US approval: 2013. South San Francisco (CA): Genentech, Inc; 2017. Available from: https://www.gene.com/download/pdf/gazyva_prescribing.pdf
   Google Scholar
• AbbVie Inc. AbbVie announces US FDA approval of Imbruvica (ibrutinib) plus obinutuzumab (Gazyva) - first chemotherapy-free, anti-CD20 combination regimen approved for chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) in previously untreated patients. North Chicago (IL): AbbVie Inc; 2019 [cited 2020 Apr 29]. Available from: https://news.abbvie.com/news/abbvie-announces-us-fda-approval-imbruvica-ibrutinib-plus-obinutuzumab-gazyva–first-chemotherapy-free-anti-cd20-combination-regimen-approved-for-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-cllsll-in-previously-untreated-pati.htm
   Google Scholar
• AbbVie Inc. AbbVie announces US FDA approval of Venclexta (venetoclax) as a chemotherapy-free option for previously untreated chronic lymphocytic leukemia patients. North Chicago (IL): AbbVie Inc; 2019 [cited 2020 Apr 29]. Available from: https://news.abbvie.com/news/press-releases/abbvie-announces-us-fda-approval-venclexta-venetoclax-as-chemotherapy-free-combination-regimen-for-previously-untreated-chronic-lymphocytic-leukemia-patients.htm
   Google Scholar
• Woyach JA, Blachly JS, Rogers KA, et al. Acalabrutinib plus obinutuzumab in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia. Cancer Discov. 2020 Mar;10(3):394–405.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 Apr 18;395(10232):1278–1291.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Gazyvaro (obinutuzumab) Summary of product characteristics. Amsterdam (The Netherlands): European Medicines Agency; 2019 [cited 2019 Nov 6]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro
   Google Scholar
• Highlights of prescribing information. IMBRUVICA® (ibrutinib). Horsham (PA): Janssen Biotech Inc; 2019 [cited 2020 Apr 29]. Available from: https://imbruvica.com/files/prescribing-information.pdf
   Google Scholar
• F. Hoffmann-La Roche Ltd. European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia. Basel (Switzerland): F. Hoffmann-La Roche Ltd; 2020 [cited 2020 Apr 29]. Available from: https://www.roche.com/media/releases/med-cor-2020-03-12.htm
   Google Scholar
• Novartis Pharmaceuticals Corporation. Highlights of prescribing information. ARZERRA®(ofatumumab) injection, for intravenous use. Initial US approval: 2009. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125326lbl.pdf
   Google Scholar
• European Medicines Agency. Arzerra (ofatumumab) Summary of product characteristics. Amsterdam (The Netherlands): European Medicines Agency; 2019 [cited 2019 Dec 19]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra
   Google Scholar
• TG Therapeutics, Inc. Pipeline: Ublituximab (TG-1101). New York (NY): TG Therapeutics; 2019 [cited 2019 Nov 6]. Available from: https://www.tgtherapeutics.com/pipeline/TGTX-1101.cfm
   Google Scholar
• Singh V, Gupta D, Almasan A. Development of novel anti-CD20 monoclonal antibodies and modulation in CD20 levels on cell surface: looking to improve immunotherapy response. J Cancer Sci Ther. 2015 Nov;7(11):347–358.
   PubMedGoogle Scholar
• Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010 June 3;115(22):4393–4402.
   PubMed Web of Science ®Google Scholar
• Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011 July 14;118(2):358–367.
   PubMed Web of Science ®Google Scholar
• Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin’s lymphomas: a glycoengineered type II CD20 antibody. Oncol Res Treat. 2015 Mar;38(4):185–192.
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Sidon L, Dovedi SJ, et al. The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab. Br J Haematol. 2013 Sep;162(6):842–845.
   PubMed Web of Science ®Google Scholar
• Honeychurch J, Alduaij W, Azizyan M, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012 Apr 12;119(15):3523–3533.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Butchar JP, Cheney C, et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol. 2013 Mar 15;190(6):2702–2711.
   PubMed Web of Science ®Google Scholar
• Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011 Apr 28;117(17):4519–4529.
   PubMed Web of Science ®Google Scholar
• Reslan L, Dalle S, Herveau S, et al. Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk Lymphoma. 2014 Jan;55(1):188–190.
   PubMed Web of Science ®Google Scholar
• Dalle S, Reslan L, Besseyre de Horts T, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther. 2011 Jan;10(1):178–185.
   PubMed Web of Science ®Google Scholar
• Zamzami N, Marchetti P, Castedo M, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 1995 Aug 1;182(2):367–377.
   PubMed Web of Science ®Google Scholar
• Hockenbery DM, Oltvai ZN, Yin XM, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993 Oct 22;75(2):241–251.
   PubMed Web of Science ®Google Scholar
• Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031–2042.
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013 Nov 14;122(20):3482–3491.
   PubMed Web of Science ®Google Scholar
• Herter S, Birk MC, Klein C, et al. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol. 2014 Mar 1;192(5):2252–2260.
   PubMed Web of Science ®Google Scholar
• Valgardsdottir R, Cattaneo I, Klein C, et al. Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. Blood. 2017 May 11;129(19):2636–2644.
   PubMed Web of Science ®Google Scholar
• Terszowski G, Klein C, Stern M. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J Immunol. 2014 June 15;192(12):5618–5624.
   PubMed Web of Science ®Google Scholar
• Grandjean CL, Montalvao F, Celli S, et al. Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies. Sci Rep. 2016 Oct 4;6:34382.
   PubMed Web of Science ®Google Scholar
• Kumar A, Planchais C, Fronzes R, et al. Binding mechanisms of therapeutic antibodies to human CD20. Science. 2020 Aug 14;369(6505):793–799.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004 Apr 1;103(7):2738–2743.
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003 Feb 1;101(3):1045–1052.
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol. 2011 Mar 15;186(6):3762–3769.
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Laprevotte E, Klein C, et al. Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers. Blood Cancer J. 2015 Nov;5:e367.
   PubMed Web of Science ®Google Scholar
• Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2011 Feb;152(3):295–306.
   PubMed Web of Science ®Google Scholar
• Reddy V, Klein C, Isenberg DA, et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford). 2017 Jul 1;56(7):1227–1237.
   PubMed Web of Science ®Google Scholar
• Palazzo A, Herter S, Grosmaire L, et al. The PI3Kdelta-selective inhibitor idelalisib minimally interferes with immune effector function mediated by rituximab or obinutuzumab and significantly augments B cell depletion in vivo. J Immunol. 2018 Apr 1;200(7):2304–2312.
   PubMed Web of Science ®Google Scholar
• Herting F, Friess T, Bader S, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014 Sep;55(9):2151–5160.
   PubMed Web of Science ®Google Scholar
• Herting F, Friess T, Umana P, et al. Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma. Leuk Lymphoma. 2018 Jun;59(6):1482–1485.
   PubMed Web of Science ®Google Scholar
• Herting F, Herter S, Friess T, et al. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388). Eur J Haematol. 2016 Nov;97(5):461–470.
   PubMed Web of Science ®Google Scholar
• Yasuhiro T, Sawada W, Klein C, et al. Anti-tumor efficacy study of the Bruton’s tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab. Leuk Lymphoma. 2016 Mar;9:1–9.
   Google Scholar
• Gockeritz E, Kerwien S, Baumann M, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015 Nov 1;137(9):2234–2242.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010 Jul 20;28(21):3525–3530.
   PubMed Web of Science ®Google Scholar
• Du J, Yang H, Guo Y, et al. Structure of the Fab fragment of therapeutic antibody ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11–12):2419–2423.
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006 July 1;177(1):362–371.
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004 Sep 15;104(6):1793–1800.
   PubMed Web of Science ®Google Scholar
• Li B, Shi S, Qian W, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 2008 Apr 1;68(7):2400–2408.
   PubMed Web of Science ®Google Scholar
• Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009 July 1;183(1):749–758.
   PubMed Web of Science ®Google Scholar
• Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol. 2012 Feb;156(4):490–498.
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Da Roit F, et al. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol. 2013 Jan 1;190(1):231–239.
   PubMed Web of Science ®Google Scholar
• Sebejova L, Borsky M, Jaskova Z, et al. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab. Exp Hematol. 2014 Oct;42(10):867–74 e1.
   PubMed Web of Science ®Google Scholar
• Barth MJ, Mavis C, Czuczman MS, et al. Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in preclinical models of mantle cell lymphoma. Clin Cancer Res. 2015 Oct 1;21(19):4391–4397.
   PubMed Web of Science ®Google Scholar
• Sawas A, Farber CM, Schreeder MT, et al. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. Br J Haematol. 2017 Apr;177(2):243–253.
   PubMed Web of Science ®Google Scholar
• Babiker HM, Glode AE, Cooke LS, et al. Ublituximab for the treatment of CD20 positive B-cell malignancies. Expert Opin Investig Drugs. 2018 Apr;27(4):407–412.
   PubMed Web of Science ®Google Scholar
• Le Garff-Tavernier M, Herbi L, de Romeuf C, et al. Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia. 2014 Jan;28(1):230–233.
   PubMed Web of Science ®Google Scholar
• de Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol. 2008 Mar;140(6):635–643.
   PubMed Web of Science ®Google Scholar
• Konno Y, Kobayashi Y, Takahashi K, et al. Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity. Cytotechnology. 2012 May;64(3):249–265.
   PubMed Web of Science ®Google Scholar
• Chenoweth AM, Wines BD, Anania JC, et al. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs. Immunol Cell Biol. 2020 Apr;98(4):287–304.
   PubMed Web of Science ®Google Scholar
• Le Garff-Tavernier M, Decocq J, de Romeuf C, et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia. 2011 Jan;25(1):101–109.
   PubMed Web of Science ®Google Scholar
• Miller J, Barth MJ, Mavis C, et al. Ublituximab (TGTX-1101), a novel anti-CD20 monoclonal antibody (mAb), demonstrates activity in rituximab-sensitive and rituximab–resistant B non-Hodgkin lymphoma (B-NHL) pre-clinical in vitro and in vivo models. Blood. 2012 Nov;120:2756.
   Web of Science ®Google Scholar
• Esteves IT, Dumontet C, Herveau S, et al. LFB-R603, a third-generation monoclonal anti-CD20 antibody displays an additive antitumor activity with antileukemic chemotherapeutic agents in mouse xenograft models. Blood. 2011 Nov;118(21):1660.
   Web of Science ®Google Scholar
• Ben Abdelwahed R, Donnou S, Ouakrim H, et al. Preclinical study of ublituximab, a glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci. 2013 May 1;54(5):3657–3665.
   PubMed Web of Science ®Google Scholar
• Donnou S, Abdelwahed-Bagga RB, Cosette J, et al. Ublituximab (TGTX-1101), a novel, third-generation anti-CD20 antibody demonstrates enhanced antitumor activity compared to rituximab in primary CNS and intraocular lymphoma murine models. Blood. 2012 Nov;120(21):2755.
   Web of Science ®Google Scholar
• Le Garff-Tavernier M, Herbi L, de Romeuf C, et al. The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstrom macroglobulinemia. Haematologica. 2015 Apr;100(4):e147–51.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Dyer MJS, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. 23rd Congress of the European Hematology Association; Stockholm (Sweden); 2018. p. S151.
   Google Scholar
• Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015 Jul;29(7):1602–1604.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101–1110.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Losic N, Ronn BB, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br J Haematol. 2010 July;150(1):58–71.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008 Feb 1;111(3):1094–1100.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Panayiotidis P, Afanasyev B, et al. A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL. Am J Hematol. 2016 Sep;91(9):900–906.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011 Nov 10;118(19):5126–5129.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1749–1755.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Brander DM, Mato AR, et al. Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: final results of the GENUINE phase III study. J Clin Oncol. 2020 May 25;38(15_suppl):8022.
   Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331–1344.
   PubMed Web of Science ®Google Scholar
• Pott C, Hoster E, Kehden B, et al. Minimal residual disease response at end of induction and during maintenance correlates with updated outcome in the phase III GALLIUM study of obinutuzumab- or rituximab-based immunochemotherapy in previously untreated follicular lymphoma patients. Blood. 2018 Nov;132(Supplement 1):396.
   Web of Science ®Google Scholar
• Davies A, Trask P, Demeter J, et al. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. Ann Hematol. 2020 Apr 20. DOI:https://doi.org/10.1007/s00277-020-04021-6
   Google Scholar
• Townsend W, Buske C, Cartron G, et al. Obinutuzumab-based immunochemotherapy prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated follicular lymphoma: four-year results from the phase III GALLIUM study. Blood. 2018 Nov;132(Supplement 1):1597.
   Web of Science ®Google Scholar
• Seymour JF, Marcus R, Davies A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019 Jun;104(6):1202–1208.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018 Aug 10;36(23):2395–2404.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015 Oct 20;33(30):3467–3474.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1081–1093.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018 Aug 1;36(22):2259–2266.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Trask PC, Gribben JG, et al. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Ann Hematol. 2017 Feb;96(2):253–259.
   PubMed Web of Science ®Google Scholar
• Pott C, Sehn LH, Belada D, et al. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Leukemia. 2020 Feb;34(2):522–532.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Fukuhara N, Ogura M, et al. A phase III study of ofatumumab vs rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab-containing therapy (HOMER): results of the interim analysis. 21st Congress of the European Hematology Association (EHA); June 9–12; Copenhagen (Denmark); 2016. p. P313.
   Google Scholar
• Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012 Apr 19;119(16):3698–3704.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017 Nov 1;35(31):3529–3537.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Martelli M, Trněný M, et al. A randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020 June 6;13(1):71.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011 July 27;476(7360):298–303.
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002 Dec;2(12):920–932.
   PubMed Web of Science ®Google Scholar
• Casasnovas R-O, Salles GA, Oberic L, et al. Obinutuzumab versus rituximab in combination with ACVBP-14 or CHOP-14 following a PET-driven strategy in Aa-IPI 1-3 DLBCL patients (<60 years): third planned interim and final analyses of the GAINED trial. Blood. 2017 Dec;130(Supplement 1):190.
   Google Scholar
• van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017 Feb 10;35(5):544–551.
   PubMed Web of Science ®Google Scholar
• Itchaki G, Brown JR. The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia. Ther Adv Hematol. 2016 Oct;7(5):270–287.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Fowler NH, Wang ML. Breakthrough therapies in B-cell non-Hodgkin lymphoma. Ann Oncol. 2016 May;27(5):778–787.
   PubMed Web of Science ®Google Scholar
• Wu J, Liu C, Tsui ST, et al. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016 Sep 2;9(1):80.
   PubMed Web of Science ®Google Scholar
• Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019 Feb 1;37(4):269–277.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019 Jun;380(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):43–56.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. IMBRUVICA summary of product characteristics. North Chicago (IL): Abbvie Inc; 2019 [cited 2020 Apr 29]. Available from: https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_en.pdf
   Google Scholar
• Celgene Corporation. Highlights of prescribing information. REVLIMID [lenalidomide] capsules, for oral use. Summit (NJ): Celgene Corporation; 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021880s034lbl.pdf
   Google Scholar
• Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018 Sep 6;379(10):934–947.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019 May 10;37(14):1188–1199.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Le Gouill S, Feugier P, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019 Aug;6(8):e429–e437.
   PubMed Web of Science ®Google Scholar
• Fowler NH, Nastoupil LJ, Chin C, et al. A phase I/II study of lenalidomide plus obinutuzumab in relapsed indolent lymphoma. Blood. 2019;134(Supplement_1):348.
   Web of Science ®Google Scholar
• Nastoupil LJ, Westin JR, Hagemeister FB, et al. Results of a phase II study of obinutuzumab in combination with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL). Blood. 2019;134(Supplement_1):125.
   Web of Science ®Google Scholar
• Michot J-M, Bouabdallah R, Vitolo U, et al. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Lancet Haematol. 2020;7(9):e649–59.
   PubMed Web of Science ®Google Scholar
• Genentech, Inc. Highlights of prescribing information. Rituxan® (rituximab) injection, for intravenous use. South San Francisco (CA): Biogen Idec, Inc. and Genentech USA, Inc; 2019. Avialable from:  https://www.gene.com/download/pdf/rituxan_prescribing.pdf
   Google Scholar
• European Medicines Agency. Mabthera Summary of product characteristics. Amsterdam (The Netherlands). European Medicines Agency. 2020 [updated 2020 Mar 25; cited 2020 Apr 29]. Available from: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf
   Google Scholar
• Davies A, Merli F, Mihaljevic B, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014 Mar;15(3):343–352.
   PubMed Web of Science ®Google Scholar
• Davies A, Merli F, Mihaljević B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017 Mar;4(6):e272–e282.
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017 Nov;102(11):1913–1922.
   PubMed Web of Science ®Google Scholar
• Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016 Mar 3;3:e128–38.
   PubMed Web of Science ®Google Scholar
• Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol. 2015 Nov;80(5):1001–1009.
   PubMed Web of Science ®Google Scholar
• Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014 Jun;32(17):1782–1791.
   PubMed Web of Science ®Google Scholar
• Roche Products Ltd. MabThera 1400 mg solution for subcutaneous injection. Welwyn Garden City (Herts): Roche Products Ltd; 2020 [updated 2020 Apr 8; cited 2020 July 1]. Available from: https://www.medicines.org.uk/emc/product/5333/smpc
   Google Scholar
• Genentech, Inc. Highlights of prescribing information: Rituxan Hycela™ (rituximab and hyaluronidase human) injection, for subcutaneous use. San Francisco (CA): Genentech, Inc; 2017 [cited 2020 July 1] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761064s000lbl.pdf.
   Google Scholar
• Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017 Apr 1;28(4):836–842.
   PubMed Web of Science ®Google Scholar
• Rule S, Briones J, Smith R, et al. Preference for rituximab subcutaneous (SC) and intravenous (IV) among patients with CD20+ non-Hodgkin’s lymphoma (NHL) completing the RASQ measure in randomized phase III studies Prefmab and Mabcute. Value Health. 2014 Nov;17(7):A537.
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, Rueda A, Avivi I, et al. Patient satisfaction with subcutaneous vs intravenous rituximab combined with CHOP for untreated diffuse large B-cell lymphoma: results from the phase IIIB MABEASE study. Hematol Oncol. 2015;33:A383.
   Google Scholar
• Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014 Jul;17(7):459–468.
   PubMedGoogle Scholar
• De Cock E, Kritikou P, Sandoval M, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One. 2016;11(6):e0157957.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information. Rituxan® (rituximab) injection, for intravenous use. South San Francisco (CA): Biogen and Genentech USA, Inc; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5450lbl.pdf
   Google Scholar
• Salles G, Barrett M, Foa R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017 Oct;34(10):2232–2273.
   PubMed Web of Science ®Google Scholar
• Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4070–4078.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008 Dec 15;112(13):4824–4831.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008 Oct 1;26(28):4579–4586.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005 Feb 15;105(4):1417–1423.
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol. 2007 May 20;25(15):1986–1992.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood. 2005 Dec 1;106(12):3725–3732.
   PubMed Web of Science ®Google Scholar
• Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14;127(2):208–215.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol. 2011 Sep 10;29(26):3559–3566.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014 Apr 20;32(12):1236–1241.
   PubMed Web of Science ®Google Scholar
• Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019 Nov 1;37(31):2815–2824.
   PubMed Web of Science ®Google Scholar
• Sun M, Zhang H. Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead. Heliyon. 2019 Mar;5(3):e01297.
   PubMed Web of Science ®Google Scholar
• Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2912–2919.
   PubMed Web of Science ®Google Scholar
• Furtado M, Dyer MJ, Johnson R, et al. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma–a phase II trial. Br J Haematol. 2014 May;165(4):575–578.
   PubMed Web of Science ®Google Scholar
• Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012 May 31;119(22):5126–5132.
   PubMed Web of Science ®Google Scholar
• Salles GA, Morschhauser F, Solal-Celigny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013 Aug 10;31(23):2920–2926.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012 May 31;119(22):5118–5125.
   PubMed Web of Science ®Google Scholar
• Kamisoglu K, Phipps A, Jamois C, et al. Greater efficacy and potency of obinutuzumab compared with rituximab in chronic lymphocytic leukemia patients confirmed by a semi-mechanistic pharmacokinetic/pharmacodynamic model. Blood. 2017 Dec;130(Supplement 1):1267.
   PubMed Web of Science ®Google Scholar
• Jamois C, Gibiansky E, Gibiansky L, et al. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. Br J Clin Pharmacol. 2019 July;85(7):1495–1506.
   PubMed Web of Science ®Google Scholar
• Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol. 2007 Apr;62(1):43–52.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19(8):2165–2170.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Wierda WG, Faderl S, et al. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL). Blood. 2005 Nov;106(11):2117.
   Google Scholar
• Friedrichs B, Nickelsen M, Ziepert M, et al. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. Br J Haematol. 2019 Mar;184(5):760–768.
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, de Nully Brown P, van der Holt B, et al. Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: results from a HOVON-Nordic lymphoma group study. J Clin Oncol. 2016 May;34(Suppl.):7504-7504. abstr 7504.
   PubMed Web of Science ®Google Scholar
• Mohty M, Dulery R, Gauthier J, et al. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant. 2020 Apr 18;55:1525–1532.
   Web of Science ®Google Scholar
• Coyle L, Morley NJ, Rambaldi A, et al. Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2020 Jun;16:1–10.
   Google Scholar
• Schuster SJ, Bartlett NL, Assouline S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019 Nov;134(Supplement_1):6.
   PubMed Web of Science ®Google Scholar
• Sun LL, Ellerman D, Mathieu M, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015 May 13;7(287):287ra70.
   PubMed Web of Science ®Google Scholar
• Bacac M, Colombetti S, Herter S, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018 Oct 1;24(19):4785–4797.
   PubMed Web of Science ®Google Scholar
• Jurczak W, Zinzani PL, Hess G, et al. A phase IIa, open-label, multicenter study of single-agent tafasitamab (MOR208), an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma: long-term follow-up, final analysis. Blood. 2019 Nov;134(Supplement_1):4078.
   Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 June 5;21:978–988.
   Web of Science ®Google Scholar
• Maddocks KJ, Duell J, Barca EG, et al. Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): response rates in patient subgroups with poor prognosis. J Clin Oncol. 2019 May;37(15_suppl):7521.
   Web of Science ®Google Scholar
• Nowakowski GS, Belada D, Molina L, et al. B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): an open-label, randomized phase II/III trial. J Clin Oncol. 2017;35(15_suppl):TPS7571.
   Web of Science ®Google Scholar
• European Medicines Agency. Yescarta: axicabtagene ciloleucel. Amsterdam (The Netherlands): European Medicines Agency; 2020 [cited 2020 June 26]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta
   Google Scholar
• US Food and Drug Administration. YESCARTA (axicabtagene ciloleucel). Silver Spring (MD): US Food and Drug Administration; 2020 [cited 2020 June 26]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel
   Google Scholar
• US Food and Drug Administration.KYMRIAH (tisagenlecleucel). Silver Spring (MD): US Food and Drug Administration; 2019 [cited 2020 June 26]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel
   Google Scholar
• US Food and Drug Administration. KYMRIAh. Tisagenlecleucel. Amsterdam (The Netherlands): European Medicines Agency; 2020 [cited 2020 June 26]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah
   Google Scholar
• Lisocabtagene Maraleucel (JCAR017) as second-line therapy (TRANSCEND-PILOT-017006). Bethesda (MD): NIH. US National Library of Medicine; 2020. (ClinicalTrials.gov). [cited 2020 Sep]. Available from: https://clinicaltrials.gov/ct2/show/NCT03483103
   Google Scholar
• Morschhauser F, Carlo-Stella C, Offner F, et al. Dual CD20-targeted therapy with concurrent CD20-TCB and obinutuzumab shows highly promising clinical activity and manageable safety in relapsed or refractory B-cell non-Hodgkin lymphoma: preliminary results from a phase Ib trial. Blood. 2019 Nov;134(Supplement_1):1584 .
   Web of Science ®Google Scholar